Company profile: NewAmsterdam Pharma
1.1 - Company Overview
Company description
- Provider of clinical-stage research and development of therapies for cardio-metabolic diseases, including obicetrapib, a selective cholesteryl ester transfer protein (CETP) inhibitor that reduces LDL-C and increases HDL-C for treating metabolic diseases.
Products and services
- Clinical-Stage Research & Development: Architects transformative therapies for cardio-metabolic diseases through clinical-stage research and development focused on discovering and advancing therapeutic candidates for metabolic indications
- Obicetrapib: A selective CETP inhibitor that reduces LDL-C and increases HDL-C to treat metabolic diseases, modulating cholesteryl ester transfer in circulating lipoproteins
- Transformative Cardio-Metabolic Therapies: Engineers transformative therapeutics aimed at cardio-metabolic diseases through focused research and development, aligning clinical-stage activities with metabolic disease treatment goals.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NewAmsterdam Pharma
NovAccess Global
HQ: United States
Website
- Description: Provider of cancer and neurological disease immunotherapies and diagnostics, combining clinical-stage asset acquisition with medical assets in the market. Through StemVax Therapeutics, develops dendritic cell-based immunotherapies for glioblastoma with TLR adjuvants, and leverages AI, bio-sensing, and blockchain-powered AI to advance diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NovAccess Global company profile →
GT Biopharma
HQ: United States
Website
- Description: Provider of TriKE immunotherapy technology that bridges natural killer cells to cancer cells to boost anti-tumor responses. Pipeline includes GTB-3550 for CD33+ leukemias (AML, high-risk MDS), GTB-3650 using camelid nanobodies for CD33+ leukemias, and GTB-5550, GTB-4550, GTB-6550 for B7H3, PD-L1, and HER2 positive solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GT Biopharma company profile →
TomegaVax
HQ: United States
Website
- Description: Provider of an immunotherapy vaccine technology platform focused on preclinical and clinical development of vaccines and immunotherapies for chronic and recurring viral infections, including HIV and HPV, addressing unmet medical needs and pursuing cures for AIDS, herpes, papillomavirus and hepatitis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TomegaVax company profile →
Themis Bioscience
HQ: Austria
Website
- Description: Provider of vaccine R&D focused on preventing infectious diseases. The start-up biotechnology company concentrates on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Themis Bioscience company profile →
Cormorant Pharma
HQ: Sweden
Website
- Description: Provider of biopharmaceutical research and development focused on IL-8's role in malignant tumors, including the HuMax-IL8 program acquired from Genmab A/S. The privately held company is based at the Karolinska Institute Science Park in Stockholm, Sweden.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cormorant Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NewAmsterdam Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NewAmsterdam Pharma
2.2 - Growth funds investing in similar companies to NewAmsterdam Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NewAmsterdam Pharma
4.2 - Public trading comparable groups for NewAmsterdam Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →